Yang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yang Yang has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Chun Jiang
Department of Biology Georgia State University Atlanta Georgia USA
10 shared publications Ningren Cui
Department of Biology, Georgia State University, 50 Decatur Street, Atlanta, Georgia
10 shared publicationsSulayman D. Dib-Hajj
Department of Neurology, Yale University School of Medicine, New Haven, Connecticut4Neurorehabilitation Research Center, Department of Neurology, Veterans Affairs Medical Center, West Haven, Connecticut
9 shared publications- Stephen G. Waxman
Yale University School of Medicine
8 shared publications Weiwei Shi
Department of Biology, Georgia State University, Atlanta, GA 30302-4010, USA
8 shared publicationsShuang Zhang
Department of Biology, Georgia State University, 50 Decatur Street, Atlanta, Georgia
6 shared publications
Latest Publications
- Open Access
- 8 September 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (36) , e35117
Conservative rehabilitation therapy for respiratory dysfunction due to phrenic nerve sacrifice during resection of massive mediastinal tumor: A case series study
Rationale: Cases of respiratory dysfunction due to phrenic nerve sacrifice during resection of massive mediastinal tumor have rarely been studied in detail. Diaphragmatic dysfunction in such cases can lead to potentially fatal respiratory and circulatory disturbances. Therefore, timely diagnosis and intervention are important. Conservative rehabilitation therapy is the first choice for respiratory dysfunction due to diaphragmatic dysfunction. Patient concerns, Diagnoses and Interventions: We present 3 patients with respiratory dysfunction due to phrenic nerve sacrifice during resection of massive mediastinal tumor. The diagnostic methods and therapeutic procedures for diaphragmatic dysfunction for each patient are described in detail. This study highlights the role of ventilator support combined with physical therapy in the treatment of respiratory dysfunction in such cases. The diagnosis of diaphragmatic dysfunction as well as the risk assessment of phrenic nerve involvement are also discussed. The modalities of ventilator support, including modes and parameters, are listed. Outcomes and Lessons: This study provides experiences of diagnosis and treatment of respiratory dysfunction due to phrenic nerve sacrifice during resection of massive mediastinal tumor. Timely diagnosis of diaphragmatic dysfunction primarily relies on clinical manifestations and radiography. Conservative rehabilitation therapy can improve or restore diaphragmatic function in majority of patients, and avert or delay the need for surgical intervention. Preoperative assessment of the risk of phrenic nerve involvement is important in such cases.
- 8 September 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (36) , e35117
Open AccessConservative rehabilitation therapy for respiratory dysfunction due to phrenic nerve sacrifice during resection of massive mediastinal tumor: A case series study
Rationale: Cases of respiratory dysfunction due to phrenic nerve sacrifice during resection of massive mediastinal tumor have rarely been studied in detail. Diaphragmatic dysfunction in such cases can lead to potentially fatal respiratory and circulatory disturbances. Therefore, timely diagnosis and intervention are important. Conservative rehabilitation therapy is the first choice for respiratory dysfunction due to diaphragmatic dysfunction. Patient concerns, Diagnoses and Interventions: We present 3 patients with respiratory dysfunction due to phrenic nerve sacrifice during resection of massive mediastinal tumor. The diagnostic methods and therapeutic procedures for diaphragmatic dysfunction for each patient are described in detail. This study highlights the role of ventilator support combined with physical therapy in the treatment of respiratory dysfunction in such cases. The diagnosis of diaphragmatic dysfunction as well as the risk assessment of phrenic nerve involvement are also discussed. The modalities of ventilator support, including modes and parameters, are listed. Outcomes and Lessons: This study provides experiences of diagnosis and treatment of respiratory dysfunction due to phrenic nerve sacrifice during resection of massive mediastinal tumor. Timely diagnosis of diaphragmatic dysfunction primarily relies on clinical manifestations and radiography. Conservative rehabilitation therapy can improve or restore diaphragmatic function in majority of patients, and avert or delay the need for surgical intervention. Preoperative assessment of the risk of phrenic nerve involvement is important in such cases.
- 8 June 2021
- Published by H1 Connect
Faculty Opinions recommendation of Therapeutic inhibition of keratinocyte TRPV3 sensory channel by local anesthetic dyclonine.
Dyclonine is a clinically used anesthetic with rapid onset and minor side effects. Its topical application relieves itching and pain, by ameliorating inflammation on mucous membranes and skin. However, its molecular target is only partially elucidated. The transient receptor potential vanilloid 3 (TRPV3) is an ion channel that senses innocuous temperature and chemical environment among other sensory modalities. TRPV3 is abundantly expressed in skin keratinocytes. Its overactivation is implicated in chronic pruritus, skin allergy, and inflammation-related skin disorders. TRPV3 dysfunctions also cause hair growth disorders in mice and Olmsted Syndrome in humans. To date, how TRPV3 could be therapeutically targeted remains to be demonstrated. This challenge has been also fueled by the lack of effective pharmacological inhibitors specifically for keratinocyte TRPV3 ion channel. In this very exciting paper, Liu et al. demonstrate that dyclonine is a potent inhibitor of the TRPV3 channel, which alleviates phenotypes caused by TRPV3 hyperactivity. Combining ion channel electrophysiology, genetic engineering and in vivo behavioral assessments, the authors found that dyclonine effectively inhibits the activity of mouse, rat, frog, and human keratinocyte TRPV3 channel. Accordingly, dyclonine rescues cell death caused by gain-of-function TRPV3 mutations. In the mouse model, dyclonine ameliorates chemically induced itching/scratching via targeting the TRPV3 channel. At the molecular level, the author uncovered single residue mutations in the pore region of the TRPV3 channel responsible for the inhibitory efficiency of dyclonine. These finding thus provides key insights for leveraging existing clinically used medications to specifically target keratinocyte TRPV3 channel. The mechanistic insight regarding the dyclonine-TRPV3 molecular interactions is also expected to help inform the development of novel therapeutics for a variety of conditions related to pain, itch, and skin inflammations.
- 8 June 2021
- Published by H1 Connect
Faculty Opinions recommendation of Therapeutic inhibition of keratinocyte TRPV3 sensory channel by local anesthetic dyclonine.
Dyclonine is a clinically used anesthetic with rapid onset and minor side effects. Its topical application relieves itching and pain, by ameliorating inflammation on mucous membranes and skin. However, its molecular target is only partially elucidated. The transient receptor potential vanilloid 3 (TRPV3) is an ion channel that senses innocuous temperature and chemical environment among other sensory modalities. TRPV3 is abundantly expressed in skin keratinocytes. Its overactivation is implicated in chronic pruritus, skin allergy, and inflammation-related skin disorders. TRPV3 dysfunctions also cause hair growth disorders in mice and Olmsted Syndrome in humans. To date, how TRPV3 could be therapeutically targeted remains to be demonstrated. This challenge has been also fueled by the lack of effective pharmacological inhibitors specifically for keratinocyte TRPV3 ion channel. In this very exciting paper, Liu et al. demonstrate that dyclonine is a potent inhibitor of the TRPV3 channel, which alleviates phenotypes caused by TRPV3 hyperactivity. Combining ion channel electrophysiology, genetic engineering and in vivo behavioral assessments, the authors found that dyclonine effectively inhibits the activity of mouse, rat, frog, and human keratinocyte TRPV3 channel. Accordingly, dyclonine rescues cell death caused by gain-of-function TRPV3 mutations. In the mouse model, dyclonine ameliorates chemically induced itching/scratching via targeting the TRPV3 channel. At the molecular level, the author uncovered single residue mutations in the pore region of the TRPV3 channel responsible for the inhibitory efficiency of dyclonine. These finding thus provides key insights for leveraging existing clinically used medications to specifically target keratinocyte TRPV3 channel. The mechanistic insight regarding the dyclonine-TRPV3 molecular interactions is also expected to help inform the development of novel therapeutics for a variety of conditions related to pain, itch, and skin inflammations.
- 2 May 2021
- Published by H1 Connect
Faculty Opinions recommendation of Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice.
Chronic pain affects more than 100 million people and fuels the national opioid crisis. However, adequate pain management without potential addiction concerns is still difficult to achieve. Human genetic studies have revealed that individuals with loss-of-function mutations in the sodium channel NaV1.7 do not feel pain at all (but otherwise are relatively healthy). Additionally, studies have found that gain-of-function mutations in the NaV1.7 channel lead to severe pain syndromes. These human genetic studies generated huge enthusiasm to target NaV1.7 for the development of next-generation painkillers. However, clinical trials evaluating small-molecule NaV1.7 blockers yield mixed and inconclusive results, suggesting further research is needed to fully realize the potential of the NaV1.7 blockade to treat pain. Most recently, antisense oligonucleotides (ASOs) and CRISPR-based interventions have emerged as promising approaches to regulate the expression (or the function) of many genes. These innovative approaches have been, or will likely be, translated to the clinical domain soon. Using CRISPR paired with “dead” Cas9 and zinc finger protein, Moreno et al. developed an approach to epigenetically repress the expression of the NaV1.7 channel, which excitingly led to long-lasting analgesia of mouse models of pain. Importantly, the authors used multiple mouse models of pain, which suggests the broad application of this approach. The safety of this approach has been evaluated as well, setting a solid foundation for further clinical translation. Notably, this study also opens up many questions for further investigation. For example, what is the major site of action of this intervention? As both dorsal root ganglion (DRG) sensory neurons and dorsal horn neurons could express the NaV1.7 channel, it is important to understand which cell type plays a leading role in this NaV1.7-suppression-related analgesia. Epigenetic repression of genes is still relatively new, and it is not clear whether this intervention is highly NaV1.7 selective or whether it can also reduce the expression of other types of sodium channels. Suppressing an array of peripheral sodium channels (NaV1.7, NaV1.8, NaV1.9), while sparing heart (NaV1.5), muscle (NaV1.4), or CNS sodium channels (NaV1.1, NaV1.2, NaV1.6) might produce an even stronger analgesic effect with minimal side effects. Could this be done with an epigenetic repression approach? In summary, this paper is very exciting and demonstrates an innovative intervention to target NaV1.7 for pain management. This new class of gene regulation approach has enormous translational potential.
- 2 May 2021
- Published by H1 Connect
Faculty Opinions recommendation of Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice.
Chronic pain affects more than 100 million people and fuels the national opioid crisis. However, adequate pain management without potential addiction concerns is still difficult to achieve. Human genetic studies have revealed that individuals with loss-of-function mutations in the sodium channel NaV1.7 do not feel pain at all (but otherwise are relatively healthy). Additionally, studies have found that gain-of-function mutations in the NaV1.7 channel lead to severe pain syndromes. These human genetic studies generated huge enthusiasm to target NaV1.7 for the development of next-generation painkillers. However, clinical trials evaluating small-molecule NaV1.7 blockers yield mixed and inconclusive results, suggesting further research is needed to fully realize the potential of the NaV1.7 blockade to treat pain. Most recently, antisense oligonucleotides (ASOs) and CRISPR-based interventions have emerged as promising approaches to regulate the expression (or the function) of many genes. These innovative approaches have been, or will likely be, translated to the clinical domain soon. Using CRISPR paired with “dead” Cas9 and zinc finger protein, Moreno et al. developed an approach to epigenetically repress the expression of the NaV1.7 channel, which excitingly led to long-lasting analgesia of mouse models of pain. Importantly, the authors used multiple mouse models of pain, which suggests the broad application of this approach. The safety of this approach has been evaluated as well, setting a solid foundation for further clinical translation. Notably, this study also opens up many questions for further investigation. For example, what is the major site of action of this intervention? As both dorsal root ganglion (DRG) sensory neurons and dorsal horn neurons could express the NaV1.7 channel, it is important to understand which cell type plays a leading role in this NaV1.7-suppression-related analgesia. Epigenetic repression of genes is still relatively new, and it is not clear whether this intervention is highly NaV1.7 selective or whether it can also reduce the expression of other types of sodium channels. Suppressing an array of peripheral sodium channels (NaV1.7, NaV1.8, NaV1.9), while sparing heart (NaV1.5), muscle (NaV1.4), or CNS sodium channels (NaV1.1, NaV1.2, NaV1.6) might produce an even stronger analgesic effect with minimal side effects. Could this be done with an epigenetic repression approach? In summary, this paper is very exciting and demonstrates an innovative intervention to target NaV1.7 for pain management. This new class of gene regulation approach has enormous translational potential.
- 19 July 2020
- Published by H1 Connect
Faculty Opinions recommendation of CaMKII enhances voltage-gated sodium channel Nav1.6 activity and neuronal excitability.
Sodium channel Nav1.6 and CaM dependent protein kinase II (CaMKII) have long been known to be key for neuronal excitability and are highly co-localized. Dysfunction of Nav1.6 can lead to excitability disorders such as neuropathic pain and epilepsy. However, how CaMKII interacts with Nav1.6 is not well understood. This study uses whole-cell voltage clamp and computational modeling to demonstrate the direct modulation of CaMKII on Nav1.6. Using mass spectrometry, they identified novel phosphorylation sites in Nav1.6. All of their proteomics data is publicly accessible. Their mutagenesis study was thorough by testing four phospho-null mutations singularly and one combination. This approach increases the robustness of the conclusion that there is a complex functional relationship of multiple phosphorylation sites for CaMKII on Nav1.6 functionality. Purkinje cells, a class of GABAergic neurons in the cerebellum, were used as the model system because Nav1.6 is the predominant sodium channel in those cells. Characterizing the effects of CaMKII on Nav1.6 fills a important knowledge gap needed to develop treatments for excitability disorders. It is also interesting to know whether CaMKII may regulate other brain sodium channels (e.g. Nav1.2) in a similar or distinct way.
- 19 July 2020
- Published by H1 Connect
Faculty Opinions recommendation of CaMKII enhances voltage-gated sodium channel Nav1.6 activity and neuronal excitability.
Sodium channel Nav1.6 and CaM dependent protein kinase II (CaMKII) have long been known to be key for neuronal excitability and are highly co-localized. Dysfunction of Nav1.6 can lead to excitability disorders such as neuropathic pain and epilepsy. However, how CaMKII interacts with Nav1.6 is not well understood. This study uses whole-cell voltage clamp and computational modeling to demonstrate the direct modulation of CaMKII on Nav1.6. Using mass spectrometry, they identified novel phosphorylation sites in Nav1.6. All of their proteomics data is publicly accessible. Their mutagenesis study was thorough by testing four phospho-null mutations singularly and one combination. This approach increases the robustness of the conclusion that there is a complex functional relationship of multiple phosphorylation sites for CaMKII on Nav1.6 functionality. Purkinje cells, a class of GABAergic neurons in the cerebellum, were used as the model system because Nav1.6 is the predominant sodium channel in those cells. Characterizing the effects of CaMKII on Nav1.6 fills a important knowledge gap needed to develop treatments for excitability disorders. It is also interesting to know whether CaMKII may regulate other brain sodium channels (e.g. Nav1.2) in a similar or distinct way.
- 16 June 2019
- Published by H1 Connect
- Vol. 160 (2)
Faculty Opinions recommendation of Comprehensive analysis of long noncoding RNA expression in dorsal root ganglion reveals cell-type specificity and dysregulation after nerve injury.
Dorsal root ganglion (DRG) neurons provide connectivity between peripheral tissues and the spinal cord. Transcriptional plasticity within DRG sensory neurons after peripheral nerve injury contributes to nerve repair but also leads to maladaptive plasticity, including the development of neuropathic pain. This study presents tissue and neuron-specific expression profiling of both known and novel long noncoding RNAs (LncRNAs) in the rodent DRG after nerve injury. We have identified a large number of novel LncRNAs expressed within the rodent DRG, a minority of which were syntenically conserved between the mouse, rat, and human, and including, both intergenic and antisense LncRNAs. We have also identified neuron type-specific LncRNAs in the mouse DRG and LncRNAs that are expressed in human IPS cell-derived sensory neurons. We show significant plasticity in LncRNA expression after nerve injury, which in mice is strain and gender dependent. This resource is publicly available and will aid future studies of DRG neuron identity and the transcriptional landscape in both the naive and injured DRG. We present our work regarding novel antisense and intergenic LncRNAs as an online searchable database, accessible from PainNetworks (http://www.painnetworks.org/). We have also integrated all annotated gene expression data in PainNetworks, so they can be examined in the context of their protein interactions.
- 16 June 2019
- Published by H1 Connect
- Vol. 160 (2)
Faculty Opinions recommendation of Comprehensive analysis of long noncoding RNA expression in dorsal root ganglion reveals cell-type specificity and dysregulation after nerve injury.
Dorsal root ganglion (DRG) neurons provide connectivity between peripheral tissues and the spinal cord. Transcriptional plasticity within DRG sensory neurons after peripheral nerve injury contributes to nerve repair but also leads to maladaptive plasticity, including the development of neuropathic pain. This study presents tissue and neuron-specific expression profiling of both known and novel long noncoding RNAs (LncRNAs) in the rodent DRG after nerve injury. We have identified a large number of novel LncRNAs expressed within the rodent DRG, a minority of which were syntenically conserved between the mouse, rat, and human, and including, both intergenic and antisense LncRNAs. We have also identified neuron type-specific LncRNAs in the mouse DRG and LncRNAs that are expressed in human IPS cell-derived sensory neurons. We show significant plasticity in LncRNA expression after nerve injury, which in mice is strain and gender dependent. This resource is publicly available and will aid future studies of DRG neuron identity and the transcriptional landscape in both the naive and injured DRG. We present our work regarding novel antisense and intergenic LncRNAs as an online searchable database, accessible from PainNetworks (http://www.painnetworks.org/). We have also integrated all annotated gene expression data in PainNetworks, so they can be examined in the context of their protein interactions.
- 20 January 2018
- Published by H1 Connect
Faculty Opinions recommendation of FGF13 Selectively Regulates Heat Nociception by Interacting with Nav1.7.
The sodium channel Nav1.7 is a major player in the pathway of pain signaling and is especially predominant in the dorsal root ganglia (DRG). Dysfunctions of this channel can lead to heat sensitivity disorders such inherited erythromelalgia (“Man on Fire Syndrome”) and lack of pain sensation caused by gain-of function or loss-of-function mutations, respectively. This paper explores another source of thermal sensitivity: Nav1.7 interaction with intracellular fibroblast growth factor 13 (FGF13). The paper itself explores many facets to test FGF13’s role in heat nociception. The mice underwent behavioral tail flick and hot plate tests as well as physiological brain functional magnetic resonance imaging (fMRI) and action potential recordings, which provides a variety of data. An expression profile of mRNA and protein was conducted, which revealed a compensation attempt by the cells. The authors demonstrated the direct interaction and specificity of FGF13 by conducting a co-immunoprecipitation pull-down assay of other DRG channels. Finally, the authors confirmed FGF13’s role by rescuing the phenotype of the knockout by adding tagged FGF13. Overall, there was an abundance of sufficient, sound evidence of FGF13’s role in the heat nociception activity of Nav1.7. This study has many pharmaceutical implications of targeting pain signaling of Nav1.7 in the DRG. Are there other factors that affect heat nociception of Nav1.7? Are there similar FGFs that cause this effect on other ion channels? Would a small molecule mimic FGF13 decrease but not completely abolish heat nociception? What is the synthesis and transport mechanism of exogenous FGF13 and could this pathway be exploited to treat pain disorders? This paper leads the way in this very novel area of research and certainly would open up many exciting research directions to deepen our understanding of the roles of Nav1.7 in pain.
- 20 January 2018
- Published by H1 Connect
Faculty Opinions recommendation of FGF13 Selectively Regulates Heat Nociception by Interacting with Nav1.7.
The sodium channel Nav1.7 is a major player in the pathway of pain signaling and is especially predominant in the dorsal root ganglia (DRG). Dysfunctions of this channel can lead to heat sensitivity disorders such inherited erythromelalgia (“Man on Fire Syndrome”) and lack of pain sensation caused by gain-of function or loss-of-function mutations, respectively. This paper explores another source of thermal sensitivity: Nav1.7 interaction with intracellular fibroblast growth factor 13 (FGF13). The paper itself explores many facets to test FGF13’s role in heat nociception. The mice underwent behavioral tail flick and hot plate tests as well as physiological brain functional magnetic resonance imaging (fMRI) and action potential recordings, which provides a variety of data. An expression profile of mRNA and protein was conducted, which revealed a compensation attempt by the cells. The authors demonstrated the direct interaction and specificity of FGF13 by conducting a co-immunoprecipitation pull-down assay of other DRG channels. Finally, the authors confirmed FGF13’s role by rescuing the phenotype of the knockout by adding tagged FGF13. Overall, there was an abundance of sufficient, sound evidence of FGF13’s role in the heat nociception activity of Nav1.7. This study has many pharmaceutical implications of targeting pain signaling of Nav1.7 in the DRG. Are there other factors that affect heat nociception of Nav1.7? Are there similar FGFs that cause this effect on other ion channels? Would a small molecule mimic FGF13 decrease but not completely abolish heat nociception? What is the synthesis and transport mechanism of exogenous FGF13 and could this pathway be exploited to treat pain disorders? This paper leads the way in this very novel area of research and certainly would open up many exciting research directions to deepen our understanding of the roles of Nav1.7 in pain.
- 12 December 2017
- Published by H1 Connect
Faculty Opinions recommendation of CaV2.2 Gates Calcium-Independent but Voltage-Dependent Secretion in Mammalian Sensory Neurons.
Dorsal root ganglion (DRG) sensory neurons help to detect a variety of sensory inputs including noxious, mechanical and thermal stimuli. Although it is traditionally believed that sensory neurons in DRG do not form a functional neural network, the interactions and coupling of sensory neurons have been suggested. One possibility for sensory neurons to interact is via the secretion of neurotransmitters and neuropeptides. A common and well understood way of secretion is Ca2+ dependent secretion (CDS). However, Ca2+ independent secretion is not well understood. In this newly published paper, Chai et al. elegantly demonstrate the molecular mechanism of the novel “Ca2+ independent but voltage-dependent secretion (CiVDS)”, involving the binding of Cav2.2 and SNARE via a “Synprint” linker. This paper also shows that for this particular secretion, the cargo is ATP. This is a beautiful mechanistic study of a foundational biological process. It also opens many more questions in the field of DRG sensory neurons. For example, why is this process only observed in primary sensory neurons but not other secretory cells? Will this process help to mediate the coupled activation of DRG sensory neurons {1}? Does CiVDS mainly function in primary spontaneous sensation or can it also contribute to pathological pain or other sensation abnormality? Addressing these interesting questions would likely help to move the field forward in exciting and unexpected ways.
- 12 December 2017
- Published by H1 Connect
Faculty Opinions recommendation of CaV2.2 Gates Calcium-Independent but Voltage-Dependent Secretion in Mammalian Sensory Neurons.
Dorsal root ganglion (DRG) sensory neurons help to detect a variety of sensory inputs including noxious, mechanical and thermal stimuli. Although it is traditionally believed that sensory neurons in DRG do not form a functional neural network, the interactions and coupling of sensory neurons have been suggested. One possibility for sensory neurons to interact is via the secretion of neurotransmitters and neuropeptides. A common and well understood way of secretion is Ca2+ dependent secretion (CDS). However, Ca2+ independent secretion is not well understood. In this newly published paper, Chai et al. elegantly demonstrate the molecular mechanism of the novel “Ca2+ independent but voltage-dependent secretion (CiVDS)”, involving the binding of Cav2.2 and SNARE via a “Synprint” linker. This paper also shows that for this particular secretion, the cargo is ATP. This is a beautiful mechanistic study of a foundational biological process. It also opens many more questions in the field of DRG sensory neurons. For example, why is this process only observed in primary sensory neurons but not other secretory cells? Will this process help to mediate the coupled activation of DRG sensory neurons {1}? Does CiVDS mainly function in primary spontaneous sensation or can it also contribute to pathological pain or other sensation abnormality? Addressing these interesting questions would likely help to move the field forward in exciting and unexpected ways.
- 15 September 2017
- Published by H1 Connect
Faculty Opinions recommendation of CDYL suppresses epileptogenesis in mice through repression of axonal Nav1.6 sodium channel expression.
From epigenetics to epilepsy, via a channel in between. Ion channels, especially voltage-gated sodium channels, play indispensable roles in electrical signal generation in neurons, and the dysfunctions of ion channels are responsible for many devastating neurological diseases including epilepsy, chronic pain and autism. Sodium channel Nav1.6 is a major regulator of action potential threshold and neuronal excitability in both the peripheral and the central nervous system, and mutations of Nav1.6 have been found in increasing numbers of patients with epilepsy. This very interesting paper by Dr Huang and his team tackles the channelopathy-related epilepsy issue via the novel lens of epigenetics. Dr Huang’s team found that an epigenetic factor called chromodomain Y-like (CDYL) protein is negatively regulated by neuronal excitability. Using an elegant ChIP-seq approach, the authors demonstrated that SCN8A (the gene encoding Nav1.6 channel) is a target of CDYL and is negatively regulated by CDYL. The authors further provided evidence suggesting that increased neuronal excitability lowers CDYL expression, which in turn upregulates Nav1.6, leading to increased seizure susceptibility. As one hallmark of seizure is hyperexcitability of neurons, this whole pathway seems like a vicious circle that could heighten epilepsy in an auto-pilot model. Shockingly, the authors also found that human brain tissues from patients with epilepsy have decreased expression of CDYL and increased expression level of SCN8A. This finding is potentially groundbreaking as it points to a completely new way of how we view human epilepsy. Further down the road, there are many important questions to be addressed in future studies. For example, is there a causal link between epilepsy and the reduction of CDYL expression in human brain tissue? Would manipulation of CDYL be a potential therapeutic intervention for epilepsy? It has recently been reported that Nav1.6 knockout in cortical excitatory neurons reduces seizures, whereas in the thalamic reticular nucleus it leads to absence seizures {1}. Is it possible that targeting CDYL (instead of targeting Nav1.6 directly) may bypass the thalamus side effects? Regardless of these open questions, this paper represents one of the landmarks in the field that is worth recommending.
- 15 September 2017
- Published by H1 Connect
Faculty Opinions recommendation of CDYL suppresses epileptogenesis in mice through repression of axonal Nav1.6 sodium channel expression.
From epigenetics to epilepsy, via a channel in between. Ion channels, especially voltage-gated sodium channels, play indispensable roles in electrical signal generation in neurons, and the dysfunctions of ion channels are responsible for many devastating neurological diseases including epilepsy, chronic pain and autism. Sodium channel Nav1.6 is a major regulator of action potential threshold and neuronal excitability in both the peripheral and the central nervous system, and mutations of Nav1.6 have been found in increasing numbers of patients with epilepsy. This very interesting paper by Dr Huang and his team tackles the channelopathy-related epilepsy issue via the novel lens of epigenetics. Dr Huang’s team found that an epigenetic factor called chromodomain Y-like (CDYL) protein is negatively regulated by neuronal excitability. Using an elegant ChIP-seq approach, the authors demonstrated that SCN8A (the gene encoding Nav1.6 channel) is a target of CDYL and is negatively regulated by CDYL. The authors further provided evidence suggesting that increased neuronal excitability lowers CDYL expression, which in turn upregulates Nav1.6, leading to increased seizure susceptibility. As one hallmark of seizure is hyperexcitability of neurons, this whole pathway seems like a vicious circle that could heighten epilepsy in an auto-pilot model. Shockingly, the authors also found that human brain tissues from patients with epilepsy have decreased expression of CDYL and increased expression level of SCN8A. This finding is potentially groundbreaking as it points to a completely new way of how we view human epilepsy. Further down the road, there are many important questions to be addressed in future studies. For example, is there a causal link between epilepsy and the reduction of CDYL expression in human brain tissue? Would manipulation of CDYL be a potential therapeutic intervention for epilepsy? It has recently been reported that Nav1.6 knockout in cortical excitatory neurons reduces seizures, whereas in the thalamic reticular nucleus it leads to absence seizures {1}. Is it possible that targeting CDYL (instead of targeting Nav1.6 directly) may bypass the thalamus side effects? Regardless of these open questions, this paper represents one of the landmarks in the field that is worth recommending.
- 1 September 2017
- Published by H1 Connect
Faculty Opinions recommendation of De novo genic mutations among a Chinese autism spectrum disorder cohort.
Genetic testing, including whole-exome sequencing and molecular inversion probes, has been a paradigm-shift approach in identifying de novo disease-causing mutations, especially for early onset diseases, which in theory are likely to have genetic components that contribute to disease onset. However, for most multi-factor diseases like autism, identifying a novel disease-causing gene is not easy, as several minor changes in multiple genes may work together and eventually result in a major disease phenotype. Therefore, to have a better understanding of the mutation landscape for these multi-factor diseases, a large cohort of patients is desired. China has more than 1.3 billion people, and the population density is high in major cities. This thus provides researchers with good opportunities to study a large cohort of patients. This paper by Wang et al. is particularly interesting for two major reasons: 1) this paper suggests that major autism risk genes have a similar overall mutation rate among ethnic groups; 2) more interestingly, this paper added another piece of strong evidence that scn2a might be the leading autism risk gene. This paper found that mutations in scn2a are present in almost 1% of all autism cases, supporting previous studies in other ethnic groups. The mutations in other brain sodium channels (scn1a and scn8a) have mainly been associated with epilepsy, but scn2a mutations are very unique cases. It is proposed that gain-of-function scn2a mutations are mainly associated with epilepsy while loss-of-function scn2a mutations are strongly associated with autism. As a few recent studies have revealed scn2a as a leading autism risk gene, further functional studies on scn2a would certainly generate powerful insights for both epilepsy and autism, two major neurological diseases.
- 1 September 2017
- Published by H1 Connect
Faculty Opinions recommendation of De novo genic mutations among a Chinese autism spectrum disorder cohort.
Genetic testing, including whole-exome sequencing and molecular inversion probes, has been a paradigm-shift approach in identifying de novo disease-causing mutations, especially for early onset diseases, which in theory are likely to have genetic components that contribute to disease onset. However, for most multi-factor diseases like autism, identifying a novel disease-causing gene is not easy, as several minor changes in multiple genes may work together and eventually result in a major disease phenotype. Therefore, to have a better understanding of the mutation landscape for these multi-factor diseases, a large cohort of patients is desired. China has more than 1.3 billion people, and the population density is high in major cities. This thus provides researchers with good opportunities to study a large cohort of patients. This paper by Wang et al. is particularly interesting for two major reasons: 1) this paper suggests that major autism risk genes have a similar overall mutation rate among ethnic groups; 2) more interestingly, this paper added another piece of strong evidence that scn2a might be the leading autism risk gene. This paper found that mutations in scn2a are present in almost 1% of all autism cases, supporting previous studies in other ethnic groups. The mutations in other brain sodium channels (scn1a and scn8a) have mainly been associated with epilepsy, but scn2a mutations are very unique cases. It is proposed that gain-of-function scn2a mutations are mainly associated with epilepsy while loss-of-function scn2a mutations are strongly associated with autism. As a few recent studies have revealed scn2a as a leading autism risk gene, further functional studies on scn2a would certainly generate powerful insights for both epilepsy and autism, two major neurological diseases.
- 29 August 2017
- Published by H1 Connect
Faculty Opinions recommendation of Generation of influenza A viruses as live but replication-incompetent virus vaccines.
Beyond the 20 Amino Acids: genetic code expansion finds its use in virus vaccine. Genetic code expansion involves modification of the natural genetic code, making one or more specific codons to encode artificial amino acids that are not among the 20 common naturally-encoded amino acids. The creation of unnatural amino acids has made many new studies possible, rendering new functions to existing proteins in a synthetic biology manner. In this very interesting paper, Dr Zhou and his team took a new angle, using a genetic code expansion approach to create a virus with a premature termination codon that can only replicate in a transgenic cell line but not a conventional cell line, largely eliminating the possibility for this engineered virus to be infectious to humans or other mammals. Interestingly, this engineered virus still elicited a robust immune response, and possibly could be used to generate live virus vaccines. This approach, described by Dr Zhou and his team, has many far-reaching implications beyond the virus vaccine field.
- 29 August 2017
- Published by H1 Connect
Faculty Opinions recommendation of Generation of influenza A viruses as live but replication-incompetent virus vaccines.
Beyond the 20 Amino Acids: genetic code expansion finds its use in virus vaccine. Genetic code expansion involves modification of the natural genetic code, making one or more specific codons to encode artificial amino acids that are not among the 20 common naturally-encoded amino acids. The creation of unnatural amino acids has made many new studies possible, rendering new functions to existing proteins in a synthetic biology manner. In this very interesting paper, Dr Zhou and his team took a new angle, using a genetic code expansion approach to create a virus with a premature termination codon that can only replicate in a transgenic cell line but not a conventional cell line, largely eliminating the possibility for this engineered virus to be infectious to humans or other mammals. Interestingly, this engineered virus still elicited a robust immune response, and possibly could be used to generate live virus vaccines. This approach, described by Dr Zhou and his team, has many far-reaching implications beyond the virus vaccine field.